SparingVision

SparingVision
SparingVision
This French startup is trying to find a cure for one of the most common forms of blindness, retinitis pigmentosa, which currently affects about two million people worldwide. SparingVision is focused on the development of an innovative gene therapy that will lead to the production of rod-derived cone-viability factor, a naturally occurring protein in the retina identified by startup’s co-founders.
Paris
biotech, medtech, Paris
2017
http://www.sparingvision.com/

Articles about SparingVision:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as SparingVision? We’re happy to assist you with our Startup Sourcing service.